{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG002","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"LAG525 dose reduction, NSCLC patients"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG002","value":"3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"LAG525 dose interruption, NSCLC patients"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG002","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"PDR001 dose reduction, NSCLC patients"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG002","value":"3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"PDR001 dose interruption, NSCLC patients"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG002","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"LAG525 dose reduction, melanoma patients"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG002","value":"4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"LAG525 dose interruption, melanoma patients"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG002","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"PDR001 dose reduction, melanoma patients"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG002","value":"4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"PDR001 dose interruption, melanoma patients"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG002","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"19"}],"units":"Participants"}],"title":"LAG525 dose reduction, RCC patients"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG002","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"19"}],"units":"Participants"}],"title":"LAG525 dose interruption, RCC patients"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG002","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"19"}],"units":"Participants"}],"title":"PDR001 dose reduction, RCC patients"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG002","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"19"}],"units":"Participants"}],"title":"PDR001 dose interruption, RCC patients"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG002","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"16"}],"units":"Participants"}],"title":"LAG525 dose reduction, mesothelioma patients"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG002","value":"5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"16"}],"units":"Participants"}],"title":"LAG525 dose interruption, mesothelioma patients"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG002","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"16"}],"units":"Participants"}],"title":"PDR001 dose reduction, mesothelioma patients"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG002","value":"5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"16"}],"units":"Participants"}],"title":"PDR001 dose interruption, mesothelioma patients"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"title":"LAG525 dose reduction, TNBC patients"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"title":"LAG525 dose interruption, TNBC patients"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"title":"PDR001 dose reduction, TNBC patients"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"title":"PDR001 dose interruption, TNBC patients"}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"93"}],"units":"Participants"}],"description":"Number of participants with at least one dose reduction of LAG525, at least one dose interruption of LAG525, at least one dose reduction of PDR001 and at least one dose interruption of PDR001.\n\nThe number of participants with dose reductions and dose interruptions of both study drugs is reported for each tumor type.","groups":[{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients naïve to anti-PD-1/PD-L1","id":"OG000","title":"Phase 2: Naive - LAG525 400 mg Q3W + PDR001 300 mg Q3W"},{"description":"Combination LAG525 600 mg + PDR001 400 mg (Q4W/Q4W) in patients naïve to anti-PD-1/PD-L1","id":"OG001","title":"Phase 2: Naive - LAG525 600 mg Q4W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients pre-treated with anti-PD-1/PD-L1","id":"OG002","title":"Phase 2: Pre-treated - LAG525 400 mg Q3W + PDR001 300 mg Q3W"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All patients in phase 2 who received at least one full or partial dose of LAG525 or PDR001.","reportingStatus":"POSTED","timeFrame":"From start of treatment until end of treatment, assessed up to 2.6 years.","title":"Phase 2: Number of Participants With Dose Reductions and Dose Interruptions of LAG525 and PDR001","type":"SECONDARY","unitOfMeasure":"Participants"}